BridgeBio Pharma, Inc. (BBIO)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research

Current Price

as of Mar 12, 2025

$32.59

P/E Ratio

N/A

Market Cap

$6.2B

Mar 19, 2024Apr 23, 2024May 29, 2024Jul 2, 2024Aug 2, 2024Sep 5, 2024Oct 8, 2024Nov 11, 2024Dec 17, 2024Jan 24, 2025Mar 12, 2025$20.00$30.00$40.00
  • BBIO
Description
Add to research

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Metrics
Add to research

Overview

  • HQPalo Alto, CA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerBBIO
  • Price$32.59+0.77%

Trading Information

  • Market cap$6.20B
  • Float81.75%
  • Average Daily Volume (1m)4,039,321
  • Average Daily Volume (3m)2,941,389
  • EPS-$2.88

Company

  • Revenue$221.90M
  • Rev growth (1yr)2,285.27%
  • Net income-$535.76M
  • Gross margin96.60%
  • EBITDA margin-257.45%
  • EBITDA-$571.29M
  • EV$6.64B
  • EV/Revenue29.94
  • P/EN/A
  • P/S27.33
  • P/BN/A
  • Debt/EquityN/A
Documents
Add to research
SEC Filings
8-K (2025-02-28)
8-K (2025-02-20)
8-K (2025-01-13)
8-K (2024-11-25)
8-K (2024-11-12)
8-K (2024-09-11)
8-K (2024-08-21)
8-K (2024-08-01)
8-K (2024-07-23)
8-K (2024-06-24)
8-K (2024-06-06)
8-K (2024-05-02)
8-K (2024-03-06)
8-K (2024-03-04)
8-K (2024-02-22)
8-K (2024-01-18)
8-K (2024-01-08)
8-K (2023-11-02)
8-K (2023-09-25)
8-K (2023-08-03)
8-K (2023-07-17)
8-K (2023-06-22)
8-K (2023-05-04)
8-K (2023-03-09)
8-K (2023-03-06)
8-K (2023-02-23)
10-Q (2024-11-12)
10-Q (2024-08-01)
10-Q (2024-05-02)
10-Q (2023-11-02)
10-Q (2023-08-03)
10-Q (2023-05-04)
10-K (2025-02-20)
10-K (2024-02-22)
10-K (2023-02-23)
Factset Street Account
Cantor Fitzgerald initiates BBIO, CABA, FDMT, others (2023-10-23T21:23:52Z)
BridgeBio Pharma to present additional data from the Phase 3 ATTRibute-CM study in patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the AHA Scientific Sessions 2023 ($29.39, 0.00) (2023-11-09T12:35:21Z)
BridgeBio Pharma shares long-term data from ongoing Phase 2 study in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) at the Annual Congress of World Muscle Society (WMS) ($25.26, 0.00) (2023-10-09T11:32:21Z)
BridgeBio Pharma reports Q3 EPS ($1.08) vs FactSet ($0.79) [11 est, ($1.00)-(0.58)] ($26.65, 0.00) (2023-11-02T11:39:56Z)
BridgeBio Pharma presents additional clinical outcomes data from the Phase 3 ATTRibute-CM study of Acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) ($27.10, 0.00) (2023-11-12T15:45:14Z)
BridgeBio Pharma initiated buy at Citi ($27.88, 0.00) (2023-11-07T12:40:50Z)
BridgeBio and Resilience announce strategic multi-year partnership to advance BBP-631, BBP-812 and future gene therapy treatments ($25.41, 0.00) (2023-10-03T11:39:47Z)
Factset
Factset Business Description